

2017, Allgemeine Pathologie Heidelberg

Blau: Erstautorenschaft; grün: Letztautorenschaft; lila: beides

**geteilte Erst- oder Letztautorenschaft*

Albrecht M, Stichel D, **Müller B**, Merkle R, Sticht C, Gretz N, Klingmüller U, **Breuhahn K**, Matthäus F. TTCA: an R package for the identification of differentially expressed genes in time course microarray data. BMC Bioinformatics. 2017 Jan 14;18(1):33. (IF: 2.448)

Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, **Bergmann F**, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, **Weichert W**, Weitz J, Glimm H. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol Med. 2017 Jul;9(7):918-932. (IF: 9.249)

Barrow TM, Klett H, Toth R, Böhm J, Gigic B, Habermann N, Scherer D, Schrotz-King P, Skender S, Abbenhardt-Martin C, Zielske L, Schneider M, Ulrich A, **Schirmacher P**, **Herpel E**, Brenner H, Busch H, Boerries M, Ulrich CM, Michels KB. Smoking is associated with hypermethylation of the APC 1A promoter in colorectal cancer: the ColoCare Study. J Pathol. 2017 Nov;243(3):366-375. (IF: 6.894)

Beck M, **Schirmacher P**, **Singer S**. Alterations of the nuclear transport system in hepatocellular carcinoma - New basis for therapeutic strategies. J Hepatol. 2017 Nov;67(5):1051-1061. (IF: 12.486)

Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hoerner-Rieber J, König L, Kappes J, Thomas M, Herth F, Heußel CP, **Warth A**, Debus J, Steins M, Rieken S. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol. 2017 Aug;134(1):205-212. (IF: 2.980)

Beuke K, Schildberg FA, **Pinna F**, Albrecht U, Liebe R, **Bissinger M**, **Schirmacher P**, Dooley S, Bode JG, Knolle PA, Kummer U, **Breuhahn K***, **Sahle S***. Quantitative and integrative analysis of paracrine hepatocyte activation by nonparenchymal cells upon lipopolysaccharide induction. FEBS J. 2017 Mar;284(5):796-813. (IF: 3.902)

Blaauwgeers H, Flieder D, **Warth A**, **Harms A**, Monkhorst K, Witte B, Thunnissen E. A Prospective Study of Loose Tissue Fragments in Non-Small Cell Lung Cancer Resection Specimens: An Alternative View to "Spread Through Air Spaces". Am J Surg Pathol. 2017 Sep;41(9):1226-1230. (IF: 5.363)

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, **Endris V**, **Kirchner M**, **Stenzinger A**, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A. Study Alliance Leukemia Investigators. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood. 2017 Mar 9;129(10):1333-1342. (IF: 13.164)

Boskamp T, Lachmund D, Oetjen J, Cordero Hernandez Y, Trede D, Maass P, Casadonte R, Kriegsmann J, **Warth A**, Dienemann H, Weichert W, **Kriegsmann M**. A new classification method for MALDI imaging mass spectrometry data acquired on formalin-fixed paraffin-embedded tissue samples. Biochim Biophys Acta. 2017 Jul;1865(7):916-926. (IF: 2.590)

Boxberg M, Jesinghaus M, Dorfner C, Mogler C, Drecoll E, **Warth A**, Steiger K, Bollwein C, Meyer P, Wolff KD, Kolk A, Weichert W. Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. *Histopathology*. 2017 Jun;70(7):1125-1137. (IF: 3.523)

Breitkopf-Heinlein K, Meyer C, König C, Gaitantzi H, Addante A, Thomas M, Wiercinska E, Cai C, Li Q, Wan F, Hellerbrand C, Valous NA, Hahnel M, Ehltng C, Bode JG, Müller-Bohl S, Klingmüller U, Altenöder J, Ilkavets I, Goumans MJ, Hawinkels LJ, Lee SJ, **Wieland M**, Mogler C, Ebert MP, Herrera B, Augustin H, Sánchez A, Dooley S, Ten Dijke P. BMP-9 interferes with liver regeneration and promotes liver fibrosis. *Gut*. 2017 May;66(5):939-954. (IF: 16.658)

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, **Warth A**, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourtis Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA. Lungscape Consortium. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. *Lung Cancer*. 2017 Sep;111:143-149. (IF: 4.294)

Budczies J, Bockmayr M, Klauschen F, **Endris V**, Fröhling S, **Schirmacher P**, Denkert C, **Stenzinger A**. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. *Genes Chromosomes Cancer*. 2017 Aug;56(8):651-659. (IF: 3.696)

Budczies J, Denkert C, Györfy B, **Schirmacher P**, **Stenzinger A**. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. *BMC Med Genomics*. 2017 Dec 6;10(1):74. (IF: 2.848)

Budczies J, **Mechtersheimer G**, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, **Endris V**, **Lier A**, **Lasitschka F**, **Penzel R**, Dietel M, Brors B, Gröschel S, Glimm H, **Schirmacher P**, **Renner M**, Fröhling S, **Stenzinger A**. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. *Oncoimmunology*. 2017 Jan 27;6(3):e1279777. (IF: 7.719)

Buzan MTA, Wetscherek A, Heussel CP, Kreuter M, Herth FJ, **Warth A**, Kauczor HU, Pop CM, Dinkel J. Texture analysis using proton density and T2 relaxation in patients with histological usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP). *PLoS One*. 2017 May 16;12(5):e0177689. (IF: 2.806)

Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, **Schirmacher P**, Büttner R, van Asperen CJ, Ray-Coquard I, **Endris V**, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. *Semin Oncol*. 2017 Jun;44(3):187-197. (IF: 6.212)

Carpenter AC, Wohlfert E, Chopp LB, Vacchio MS, Nie J, Zhao Y, Shetty J, Xiao Q, Deng C, Tran B, Cam M, **Gaida MM**, Belkaid Y, Bosselut R. Control of Regulatory T Cell Differentiation by the Transcription

Factors Thpok and LRF. *J Immunol.* 2017 Sep 1;199(5):1716-1728. (IF: 4.856)

Carr PR, Jansen L, Bienert S, **Roth W**, **Herpel E**, Kloor M, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M. Associations of red and processed meat intake with major molecular pathological features of colorectal cancer. *Eur J Epidemiol.* 2017 May;32(5):409-418. (IF: 7.226)

Castven D, Fischer M, Becker D, Heinrich S, Andersen JB, Strand D, Sprinzl MF, Strand S, Czauderna C, Heilmann-Heimbach S, **Roessler S**, Weinmann A, Wörns MA, Thorgeirsson SS, Galle PR, Matter MS, Lang H, Marquardt JU. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. *Oncotarget.* 2017 Jul 25;8(30):48688-48700. (IF: 5.168)

Chudasama P, **Renner M**, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweißinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, **Schirmacher P**, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, **Mechtersheimer G**, Specht K, Fröhling S. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. *Clin Cancer Res.* 2017 Feb 15;23(4):962-973. (IF: 9.619)

Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM, Meister M, Muley T, **Warth A**, Platten M, Hentze MW, Cerwenka A, Muckenthaler MU. Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. *Front Immunol.* 2017 Nov 8;8:1479. (IF: 6.429)

Czink E, Kloor M, **Goepfert B**, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, **Schirmacher P**, Doeberitz MVK, Jäger D, Springfield C. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. *Cold Spring Harb Mol Case Stud.* 2017 Sep 1;3(5). pii: a001974. (IF: new journal, IF unknown)

de Vries EM, de Krijger M, Färkkilä M, Arola J, **Schirmacher P**, Gotthardt D, **Goepfert B**, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, Sempoux C, Beuers U, Hübscher SG, Verheij J, Ponsioen CY. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. *Hepatology.* 2017 Mar;65(3):907-919. (IF: 13.246)

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, **Sinn P**, Schem C, Hanusch C, Untch M, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol.* 2018 Jan;19(1):40-50. (IF: 33.900)

Dieter SM, Giessler KM, **Kriegsmann M**, Dubash TD, Möhrmann L, Schulz ER, Siegl C, Weber S, Strakerjahn H, Oberlack A, Heger U, Gao J, Hartinger EM, Oppel F, Hoffmann CM, Ha N, Brors B, **Lasitschka F**, Ulrich A, Strobel O, Schmidt M, von Kalle C, Schneider M, **Weichert W**, Ehrenberg KR, Glimm H, Ball CR. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. *Int J Cancer.* 2017 Mar 15;140(6):1356-1363. (IF: 6.513)

Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, **Penzel R, Kriegsmann M**, Reuss DE, **Schirmacher P, Stenzinger A**, Federspil PA, **Weichert W**, Glimm H, Fröhling S. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. *Ann Oncol*. 2017 Jan 1;28(1):142-148. (IF: 11.855)

Dietz S, **Harms A, Endris V**, Eichhorn F, **Kriegsmann M, Longuespée R, Stenzinger A**, Sültmann H, **Warth A, Kazdal D**. Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas. *Int J Cancer*. 2017 Nov 1;141(9):1841-1848. (IF: 6.513)

Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, **Volckmar AL, Stenzinger A**, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. *Oncotarget*. 2017 May 23;8(43):74049-74057. (IF: 5.168)

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, **Wieczorek K**, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction. *J Urol*. 2017 Sep;198(3):575-582. (IF: 5.157)

Faehling M, Schwenk B, Kramberg S, Eckert R, **Volckmar AL, Stenzinger A***, Sträter J*. Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. *Oncotarget*. 2017 Sep 13;8(44):77897-77914. (IF: 5.168)

Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Maily L, Reynolds GM, Ashcroft M, Balfe P, Baumert TF, **Roessler S**, Wakelam MJO, McKeating JA. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication. *J Hepatol*. 2017 May;66(5):919-929. (IF: 12.486)

Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel M, Vollbrecht C, **Penzel R, Volckmar AL, Stenzinger A, Endris V**, Jung A, Lehmann U, Zeugner S, Baretton G, Kreipe H, **Schirmacher P**, Kirchner T, Dietel M, Büttner R, Merkelbach-Bruse S. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. *Virchows Arch*. 2017 Oct;471(4):509-520. (IF: 2.848)

Fisseler-Eckhoff A, **Warth A**. [Report of the Working Group on Thoracic Pathology of the German Society of Pathology 2017]. *Pathologe*. 2017 Nov;38(Suppl 2):242-244. (IF: 0.509)

Flechsig P, Frank P, Kratochwil C, Antoch G, Rath D, Moltz J, Rieser M, **Warth A**, Kauczor HU, Schwartz LH, Haberkorn U, Giesel FL. Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients. *Mol Imaging Biol*. 2017 Apr;19(2):315-322. (IF: 3.466)

Foersch S, Schindeldecker M, **Keith M**, Tagscherer KE, Fernandez A, Stenzel PJ, Pahernik S, Hohenfellner M, **Schirmacher P**, Roth W, **Macher-Goeppinger S**. Prognostic relevance of androgen receptor expression in renal cell carcinomas. *Oncotarget*. 2017 Sep 11;8(45):78545-78555. (IF: 5.168)

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, **Stenzinger A**, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T. Genomics of Immunotherapy-Associated Hyperprogressors-Letter. *Clin Cancer Res*. 2017 Oct 15;23(20):6374-6375. (IF: 9.619)

Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, Bonekamp D, Kopka K, Eder M, Heusser T, Kachelriess M, **Wieczorek K**, Sachpekidis C, Flechsig P, Giesel F, Hohenfellner M, Haberkorn U, Schlemmer HP, Dimitrakopoulou-Strauss A. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. *Eur J Nucl Med Mol Imaging*. 2017 May;44(5):776-787. (IF: 7.277)

Fricke F, Lee J, Michalak M, Warnken U, **Hausser I**, Suarez-Carmona M, Halama N, Schnölzer M, Kopitz J, Gebert J. TGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells. *Cell Commun Signal*. 2017 Apr 4;15(1):14. (IF: 3.943)

Gaiser MR, **Hausser I**, Hassel JC. Spiny keratoderma of the palms and soles - once seen, never forgotten. *J Dtsch Dermatol Ges*. 2017 Sep;15(9):938-940. (IF: 2.865)

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, **Warth A**, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. *J Clin Oncol*. 2017 May 1;35(13):1403-1410. (IF: 24.008)

Ghassem-Zadeh S, **Gaida MM**, Szanyi S, Acha-Orbea H, Frossard JL, Hinz U, Hackert T, Strobel O, Felix K. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. *J Transl Med*. 2017 Jun 2;15(1):126. (IF: 3.786)

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, **Grabe N**, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. *Eur J Nucl Med Mol Imaging*. 2017 Apr;44(4):678-688. (IF: 7.277)

Giusca S, Mereles D, Ochs A, Buss S, André F, Seitz S, Riffel J, Fortner P, **Andrulis M**, Schönland S, Katus HA, Korosoglou G. Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre. *Int J Cardiovasc Imaging*. 2017 Jun;33(6):879-888. (IF: 1.896)

Goepfert B. Biliary tract cancers: Molecular characterization and identification of novel prognostic markers. *Pathologe*. 2017 Nov;38(Suppl 2):192-197. (IF: 0.509)

Goepfert B, Roessler S, Becker N, Zucknick M, Vogel MN, Warth A, Pathil-Warth A, Mehrabi A,

Schirmacher P, Mollenhauer J, Renner M. DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data. *Histopathology*. 2017 Jun;70(7):1064-1071. (IF: 3.523)

Görtz M, Galli U, **Longerich T**, Zöller M, Erb U, Schemmer P. De novo synthesis of C4.4A in hepatocellular carcinoma promotes migration and invasion of tumor cells. *Oncol Rep*. 2017 Nov;38(5):2697-2704. (IF: 2.662)

Golriz M, Ashrafi M, Khajeh E, Majlesara A, **Flechtenmacher C**, Mehrabi A. Establishing a Porcine Model of Small for Size Syndrome following Liver Resection. *Can J Gastroenterol Hepatol*. 2017;2017:5127178. Epub 2017 Aug 29. (IF: 2.147)

Golriz M, Fonouni H, Kuttymuratov G, Esmaeilzadeh M, Rad MT, Jarahian P, **Longerich T**, Faridar A, Abbasi S, Mehrabi A, Gebhard MM. Influence of a modified preservation solution in kidney transplantation: A comparative experimental study in a porcine model. *Asian J Surg*. 2017 Apr;40(2):106-115. (IF: 1.203)

Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, **Herpel E**, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, **Sinn P**, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncol*. 2017 Dec 1;3(12):e173290. (IF: 16.559)

Goyal A, Fiškin E, Gutschner T, Polycarpou-Schwarz M, Groß M, Neugebauer J, Gandhi M, Caudron-Herger M, Benes V, Diederichs S. A cautionary tale of sense-antisense gene pairs: independent regulation despite inverse correlation of expression. *Nucleic Acids Res*. 2017 Dec 1;45(21):12496-12508. (IF: 10.162)

Goyal A, Myacheva K, Groß M, Klingenberg M, Duran Arqué B, Diederichs S. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. *Nucleic Acids Res*. 2017 Feb 17;45(3):e12. (IF: 10.162)

Graham RP, Yeh MM, Lam-Himlin D, Roberts LR, Terracciano L, Cruise MW, Greipp PT, Zreik RT, Jain D, Zaid N, Salaria SN, Jin L, Wang X, Rustin JG, Kerr SE, Sukov WR, Solomon DA, Kakar S, Waterhouse E, Gill RM, Ferrell L, Alves VA, Nart D, Yilmaz F, **Roessler S**, Longerich T, **Schirmacher P**, Torbenson MS. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. *Mod Pathol*. 2018 Jan;31(1):141-149. (IF: 5.728)

Grünow J, Rong C, Hischmann J, Zaoui K, **Flechtenmacher C**, Weber KJ, Plinkert P, Hess J. Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells. *J Exp Clin Cancer Res.* 2017 Feb 6;36(1):25. (IF: 5.189)

Guo M, Tomoshige K, Meister M, Muley T, Fukazawa T, Tsuchiya T, Karns R, **Warth A**, Fink-Baldauf IM, Nagayasu T, Naomoto Y, Xu Y, Mall MA, Maeda Y. Gene signature driving invasive mucinous adenocarcinoma of the lung. *EMBO Mol Med.* 2017 Apr;9(4):462-481. (IF: 9.249)

Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, **Stenzinger A**, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfield C, Ungerechts G. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. *BMC Cancer.* 2017 Aug 29;17(1):576. (IF: 3.288)

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, **Wieczorek K**, Hohenfellner M, Kastner C, Hadaschik B. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. *BJU Int.* 2017 Nov;120(5):631-638. (IF: 4.439)

Harati K, Behr B, Daigeler A, Hirsch T, Jacobsen F, **Renner M**, Harati A, Wallner C, Lehnhardt M, Becerikli M. Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. *Nutr Cancer.* 2017 Feb-Mar;69(2):340-351. (IF: 2.447)

Harati K, Behr B, Wallner C, Daigeler A, Hirsch T, Jacobsen F, **Renner M**, Harati A, Lehnhardt M, Becerikli M. Anti-proliferative activity of epigallocatechin-3-gallate and silibinin on soft tissue sarcoma cells. *Mol Med Rep.* 2017 Jan;15(1):103-110. (IF: 1.692)

Harms A, Kriegsmann M, Fink L, Länger F, Warth A. [The new TNM classification for lung tumors : Changes and the assessment of multiple tumor foci]. *Pathologe.* 2017 Feb;38(1):11-20. (IF: 0.509)

Has C, Schumann H, Leppert J, He Y, Hartmann B, **Hausser I**, Kohlhase J. Monoallelic Large Intragenic KRT5 Deletions Account for Genetically Unsolved Cases of Epidermolysis Bullosa Simplex. *J Invest Dermatol.* 2017 Oct;137(10):2231-2234. (IF: 6.287)

Hatiboglu G, Hohenfellner M, Arslan A, Hadaschik B, Teber D, Radtke JP, Hallscheidt P, Tolstov Y, **Roth W**, Grüllich C, Huesing J, Duensing S, Pahernik S. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. *Langenbecks Arch Surg.* 2017 Jun;402(4):637-644. (IF: 2.203)

Hatiboglu G, Simpfendörfer T, Uhlmann L, Bergero MA, **Macher-Goepfing S**, Pahernik S, Hadaschik B, Hohenfellner M, Teber D. A prospective randomized controlled trial for assessment of perineal hydrodissection technique for nervesparing robot assisted radical prostatectomy. *Int J Med Robot.* 2017 Dec;13(4). (IF: 1.613)

Hausser, I. Classification, diagnosis, and pathogenesis of rare heritable connective tissue disorders: The impact of differential ultrastructural aberrations of dermal connective tissue components. *Ultrastruct Pathol.* 2017 Jan-Feb;41(1):71-72. (IF: 0.694)

Hausser, I. Ichthyoses: new insights unravel defects in skin barrier function resulting in diverse clinical and morphological phenotypes. *Br J Dermatol.* 2017 Apr;176(4):863-864. (IF: 4.706)

Heinz L, Kim GJ, Marrakchi S, Christiansen J, Turki H, Rauschendorf MA, Lathrop M, **Hausser I**, Zimmer AD, Fischer J. Mutations in *SULT2B1* Cause Autosomal-Recessive Congenital Ichthyosis in Humans. *Am J Hum Genet.* 2017 Jun 1;100(6):926-939. (IF: 9.025)

Hermanns C, Hampl V, **Holzer K**, Aigner A, Penkava J, Frank N, Martin DE, Maier KC, **Waldburger N**, **Roessler S**, Goppelt-Struebe M, Akrap I, Thavamani A, **Singer S**, Nordheim A, Gudermann T, Muehlich S. The novel *MKL* target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma. *Oncogene.* 2017 Jun 15;36(24):3464-3476. (IF: 7.519)

Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, **Warth A**, Agaimy A. *SMARCA4* and *SMARCA2* deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. *Ann Diagn Pathol.* 2017 Feb;26:47-51. (IF: 1.734)

Hess AK, Mürer A, Mairinger FD, Weichert W, **Stenzinger A**, Hummel M, Budach V, Tinhofer I. *MiR-200b* and *miR-155* as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. *Eur J Cancer.* 2017 May;77:3-12. (IF: 6.029)

Hörner-Rieber J, Bernhardt D, Dern J, König L, Adeberg S, Paul A, Heussel CP, Kappes J, Hoffmann H, Herth FJP, Debus J, **Warth A**, Rieken S. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. *Radiother Oncol.* 2017 Nov;125(2):317-324. (IF: 4.328)

Holzer K, **Drucker E**, **Roessler S**, Dauch D, Heinzmann F, **Waldburger N**, **Eiteneuer EM**, **Herpel E**, **Breuhahn K**, Zender L, **Schirmacher P**, Ori A, **Singer S**. Proteomic Analysis Reveals *GMP Synthetase* as *p53* Repression Target in Liver Cancer. *Am J Pathol.* 2017 Feb;187(2):228-235. (IF: 4.057)

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Georg C, Meißburger B, Wolf S, Schulz A, **Penzel R**, **Herpel E**, **Kirchner M**, **Lier A**, **Endris V**, **Singer S**, **Schirmacher P**, Weichert W, **Stenzinger A**, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S. Precision oncology based on omics data: The NCT Heidelberg experience. *Int J Cancer.* 2017 Sep 1;141(5):877-886. (IF: 6.513)

Jäkel C, **Bergmann F**, Toth R, Assenov Y, van der Duin D, Strobel O, Hank T, Klöppel G, Dorrell C, Grompe M, Moss J, Dor Y, **Schirmacher P**, Plass C, Popanda O, Schmezer P. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. *Nat Commun.* 2017 Nov 6;8(1):1323. (IF: 12.124)

Jaskulski S, Jung AY, Rudolph A, Johnson T, Thöne K, **Herpel E**, **Sinn P**, Chang-Claude J. Genistein and enterolactone in relation to Ki-67 expression and HER2 status in postmenopausal breast cancer patients. *Mol Nutr Food Res.* 2017 Nov;61(11). (IF: 4.323)

Jesinghaus M, Boxberg M, Konukiewitz B, Slotta-Huspenina J, Schlitter AM, Steiger K, Specht K, **Wieczorek K, Warth A**, Schmidt T, Hartmann A, Demir IE, Feith M, Ott K, Weichert W. A Novel Grading System Based on Tumor Budding and Cell Nest Size Is a Strong Predictor of Patient Outcome in Esophageal Squamous Cell Carcinoma. *Am J Surg Pathol*. 2017 Aug;41(8):1112-1120. (IF: 5.363)

Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, **Penzel R, Endris V**, Arsenic R, Hermann G, **Stenzinger A**, Weichert W, Pfarr N, Klöppel G. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. *Mod Pathol*. 2017 Apr;30(4):610-619. (IF: 5.728)

Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecolli E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, **Wieczorek K**, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. *Oncotarget*. 2017 Jul 18;8(29):46756-46768. (IF: 5.168)

Kaiser J, Fritz S, Klauss M, **Bergmann F**, Hinz U, Strobel O, Schneider L, Büchler MW, Hackert T. Enucleation: A treatment alternative for branch duct intraductal papillary mucinous neoplasms. *Surgery*. 2017 Mar;161(3):602-610. (IF: 3.904)

Kastenhuber ER, Lalazar G, Houlihan SL, **Tschaharganeh DF**, Baslan T, Chen CC, Requena D, Tian S, Bosbach B, Wilkinson JE, Simon SM, Lowe SW. DNAJB1-PRKACA fusion kinase interacts with β -catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. *Proc Natl Acad Sci U S A*. 2017 Dec 12;114(50):13076-13084. (IF: 9.661)

Kather JN, Poleszczuk J, Suarez-Carmona M, Krisam J, Charoentong P, Valous NA, Weis CA, **Tavernar L**, Leiss F, **Herpel E**, Klupp F, Ulrich A, Schneider M, Marx A, Jäger D, Halama N. In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer. *Cancer Res*. 2017 Nov 15;77(22):6442-6452. (IF: 9.122)

Kather JN, Zöllner FG, Schad LR, Melchers SM, **Sinn HP**, Marx A, Gaiser T, Weis CA. Identification of a characteristic vascular belt zone in human colorectal cancer. *PLoS ONE* 03/2017; 12(3):e0171378. (IF: 2.806)

Kazdal D, Harms A, Endris V, Penzel R, Kriegsmann M, Eichhorn F, Muley T, Stenzinger A, Pfarr N, Weichert W, Warth A. Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. *Br J Cancer*. 2017 Jul 11;117(2):220-226. (IF: 6.176)

Kesch C, Radtke JP, Popeneciu IV, Gasch C, Dieffenbacher SC, Klein T, Schlemmer HP, **Wieczorek K**, Zogal P, Hohenfellner M, Sakas G, Hadaschik BA. TOP: Prospective Evaluation of a Volume Based, Computer Assisted Method for Transperineal Optimized Prostate Biopsy. *Urol Int*. 2017;99(2):149-155. (IF: 1.611)

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, **Ellert E**, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, **Wieczorek K**, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M,

Kopka K, Haberkorn U, Hadaschik BA, Giesel FL. Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. *J Nucl Med.* 2017 Nov;58(11):1805-1810. (IF: 6.646)

Klingenberg M, Matsuda A, **Diederichs S**, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. *J Hepatol.* 2017 Sep;67(3):603-618. (IF: 12.486)

Klöss V, Grünvogel O, Wabnitz G, Eigenbrod T, Ehrhardt S, **Lasitschka F**, Lohmann V, Dalpke AH. Interaction and Mutual Activation of Different Innate Immune Cells Is Necessary to Kill and Clear Hepatitis C Virus-Infected Cells. *Front Immunol.* 2017 Sep 29;8:1238. (IF: 6.429)

Köhler BC, **Waldburger N**, Schlamp K, Jäger D, Weiss KH, Schulze-Bergkamen H, **Schirmacher P**, Springfield C. Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. *Oncotarget.* 2017 Jun 5;8(35):59991-59998. (IF: 5.168)

Koelsche C, Schimpf D, Tharun L, Roth E, Sturm D, Jones DTW, Renker EK, Sill M, Baude A, Sahn F, Capper D, Bewerunge-Hudler M, Hartmann W, Kulozik AE, Petersen I, Flucke U, Schreuder HWB, Büttner R, Weber MA, **Schirmacher P**, Plass C, Pfister SM, von Deimling A, **Mechtersheimer G**. Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. *Clin Sarcoma Res.* 2017 May 4;7:9. eCollection 2017. (IF: NK)

Kreyzy N, Gotzian C, Fleming T, **Flechtenmacher C**, Grabe N, Plinkert P, Hess J, Zaoui K. Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma. *BMC Cancer.* 2017 May 26;17(1):382. (IF: 3.288)

Kriegsmann K, Heilig C, Cremer M, Novotny P, **Kriegsmann M**, Bruckner T, Müller-Tidow C, Egerer G, Wuchter P. Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients. *Eur J Haematol.* 2017 Nov;99(5):459-464. (IF: 2.653)

Kriegsmann M, Wandernoth P, Lisenko K, Casadonte R, Longuespée R, Arens N, Kriegsmann J. Detection of HPV subtypes by mass spectrometry in FFPE tissue specimens: a reliable tool for routine diagnostics. *J Clin Pathol.* 2017 May;70(5):417-423. (IF: 2.687)

Kriegsmann M, Longuespée R, Wandernoth P, Mohanu C, Lisenko K, Weichert W, **Warth A**, Dienemann H, De Pauw E, Katzenberger T, Aust D, Baretton G, Kriegsmann J, Casadonte R. Typing of colon and lung adenocarcinoma by high throughput imaging mass spectrometry. *Biochim Biophys Acta.* 2017 Jul;1865(7):858-864. (IF: 2.590)

Kynast K Lydia, **Volk N**, Fleming T, **Herpel E**. Diabetes-Associated Biobanking: More Topical Than Ever? *Exp Clin Endocrinol Diabetes.* 2017 Oct;125(9):603-609. (IF: 1.685)

Lasitschka F, Giese T, Paparella M, Kurzhals SR, Wabnitz G, Jacob K, Gras J, Bode KA, Heninger AK, Sziskzai T, Samstag Y, Leszinski C, Jocher B, Al-Saeedi M, Meuer SC, Schröder-Braunstein J. Human monocytes downregulate innate response receptors following exposure to the microbial metabolite

n-butyrate. *Immun Inflamm Dis.* 2017 Dec;5(4):480-492. (IF: NK)

Leichsenring J*, **Volckmar AL***, Magios N, **Morais de Oliveira CM**, **Penzel R**, **Brandt R**, **Kirchner M**, Bozorgmehr F, Thomas M, **Schirmacher P**, **Warth A**, **Endris V**, **Stenzinger A**. Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. *Genes Chromosomes Cancer.* 2017 Mar;56(3):214-220. (IF: 3.696)

Li S, Korkmaz-Icöz S, Radovits T, Ruppert M, Spindler R, Loganathan S, Hegedűs P, Brlecic P, Theisinger B, Theisinger S, Höger S, Brune M, **Lasitschka F**, Karck M, Yard B, Szabó G. Donor Preconditioning After the Onset of Brain Death With Dopamine Derivate n-Octanoyl Dopamine Improves Early Posttransplant Graft Function in the Rat. *Am J Transplant.* 2017 Jul;17(7):1802-1812. (IF: 6.165)

Lisenko K, Baertsch MA, Meiser R, Pavel P, Bruckner T, **Kriegsmann M**, Schmitt A, Witzens-Harig M, Ho AD, Hillengass J, Wuchter P. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. *Transfusion.* 2017 Oct;57(10):2359-2365. (IF: 3.386)

Lisenko K, Dingeldein G, Cremer M, **Kriegsmann M**, Ho AD, Rieger M, Witzens-Harig M. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. *BMC Cancer.* 2017 May 22;17(1):359. (IF: 3.288)

Lisenko K, **Leichsenring J**, **Zgorzelski C**, **Longuespée R**, Casadonte R, **Harms A**, **Kazdal D**, **Stenzinger A**, **Warth A**, **Kriegsmann M**. Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays. *Appl Immunohistochem Mol Morphol.* 2017 Oct;25(9):e74-e79. (IF: 1.634)

Lisenko K, Pavel P, **Kriegsmann M**, Bruckner T, Hillengass J, Goldschmidt H, Witzens-Harig M, Ho AD, Wuchter P. Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation. *Biol Blood Marrow Transplant.* 2017 Apr;23(4):684-690. (IF: 4.704)

Longuespée R, Casadonte R, **Kriegsmann M**, Wandernoth P, Lisenko K, Mazzucchelli G, Becker M, **Kriegsmann J**. Proteomic investigation of human cystic echinococcosis in the liver. *Mol Biochem Parasitol.* 2017 Jan;211:9-14. (IF: 2.536)

Macher-Goeppinger S, **Keith M**, **Endris V**, **Penzel R**, **Tagscherer KE**, Pahernik S, Hohenfellner M, Gardner H, Grüllich C, **Schirmacher P**, **Roth W**. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. *Oncotarget.* 2017 Jan 3;8(1):1046-1057. (IF: 5.168)

Macher-Goeppinger S, **Keith M**, Hatiboglu G, Hohenfellner M, **Schirmacher P**, **Roth W**, **Tagscherer KE**. Expression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas. *Transl Oncol.* 2017 Dec;10(6):869-875. (IF: 3.025)

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, **Oliveira C**, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C. DNA

copy number changes define spatial patterns of heterogeneity in colorectal cancer. *Nat Commun.* 2017 Jan 25;8:14093. (IF: 12.124)

Marquard S, Thomann S, Weiler SME, Sticht C, Gretz N, Schirmacher P, Breuhahn K. Nonautonomous effects of oncogenic YAP in hepatocarcinogenesis. *Pathologe.* 2017 Nov;38(Suppl 2):175-179. (IF: 0.509)

Matt U, Selchow P, Dal Molin M, Strommer S, Sharif O, Schilcher K, Andreoni F, **Stenzinger A**, Zinkernagel AS, Zeitlinger M, Sander P, Nemeth J. Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. *Int J Antimicrob Agents.* 2017 Jul;50(1):55-62. (IF: 4.307)

Méndez-Lucas A, Li X, Hu J, Che L, Song X, Jia J, Wang J, Xie C, Driscoll PC, **Tschaharganeh DF**, Calvisi DF, Yuneva M, Chen X. Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities. *Cancer Res.* 2017 Aug 15;77(16):4355-4364. (IF: 9.122)

Meyer IS, Jungmann A, Dieterich C, Zhang M, **Lasitschka F**, Werkmeister S, Haas J, Müller OJ, Boutros M, Nahrendorf M, Katus HA, Hardt SE, Leuschner F. The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction. *EMBO Mol Med.* 2017 Sep;9(9):1279-1293. (IF: 9.249)

Milewski D, Balli D, Ustiyani V, Le T, Dienemann H, **Warth A, Breuhahn K**, Whitsett JA, Kalinichenko VV, Kalin TV. FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. *PLoS Genet.* 2017 Dec 21;13(12):e1007097. (IF: 6.100)

Mogler C, König C, Wieland M, Runge A, Besemfelder E, Komljenovic D, Longerich T, Schirmacher P, Augustin HG. Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin. *EMBO Mol Med.* 2017 Jun;9(6):741-749. (IF: 9.249)

Mracsko E, Stegemann-Koniszewski S, Na SY, Dalpke A, Bruder D, **Lasitschka F**, Veltkamp R. A Mouse Model of Post-Stroke Pneumonia Induced by Intra-Tracheal Inoculation with *Streptococcus pneumoniae*. *Cerebrovasc Dis.* 2017;43(3-4):99-109. (IF: 2.974)

Müller H, Weiss C, **Renner M**, Felderhoff-Müser U, Mollenhauer J. DMBT1 promotes basal and meconium-induced nitric oxide production in human lung epithelial cells in vitro. *Histochem Cell Biol.* 2017 Mar;147(3):389-397. (IF: 2.553)

Mueller J, Raisi H, Rausch V, Peccerella T, Simons D, Ziener CH, Schlemmer HP, Seitz HK, **Waldburger N**, Longerich T, Straub BK, Mueller S. Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer. *J Hepatol.* 2017 Sep;67(3):535-542. (IF: 12.486)

Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, **Straub BK**, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. *Hepatology.* 2017 Jul;66(1):96-107. (IF: 13.246)

Natoni A, Smith TAG, Keane N, McEllistim C, Connolly C, Jha A, **Andrulis M, Ellert E**, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O'Dwyer ME. E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. *Leukemia*. 2017 Dec;31(12):2642-2651. (IF: 11.702)

Neumann MH, Schneck H, Decker Y, Schömer S, Franken A, **Endris V**, Pfarr N, Weichert W, Niederacher D, Fehm T, Neubauer H. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™. *Biotechnol Prog*. 2017 Jan;33(1):125-132. (IF: 1.986)

Nientiedt C, Heller M, **Endris V, Volckmar AL**, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, **Schirmacher P**, Sültmann H, **Stenzinger A**, Hohenfellner M, Grüllich C, Duensing S. Mutations in BRCA2 and taxane resistance in prostate cancer. *Sci Rep*. 2017 Jul 4;7(1):4574. (IF: 4.259)

Nientiedt C, Tolstov Y, **Volckmar AL, Endris V**, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, **Stenzinger A**, Hohenfellner M, Grüllich C, Duensing S. PARP inhibition in BRCA2-mutated prostate cancer. *Ann Oncol*. 2017 Jan 1;28(1):189-191. (IF: 11.855)

Noberini R, **Longuespée R**, Richichi C, Pruneri G, **Kriegsmann M**, Pelicci G, Bonaldi T. PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples. *Clin Epigenetics*. 2017 Jul 11;9:69. eCollection 2017. (IF: 4.987)

Nötzold L, Frank L, Gandhi M, Polycarpou-Schwarz M, Groß M, Gunkel M, Beil N, Erfle H, Harder N, Rohr K, Trendel J, Krijgsveld J, **Longerich T, Schirmacher P, Boutros M, Erhardt S, Diederichs S**. The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells. *Sci Rep*. 2017 May 23;7(1):2265. (IF: 4.259)

Nwosu ZC, Megger DA, Hammad S, Sitek B, **Roessler S**, Ebert MP, Meyer C, Dooley S. Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma. *Cell Mol Gastroenterol Hepatol*. 2017 May 31;4(2):303-323.e1. (IF: new journal, IF unknown)

Oji V, Preil ML, Kleinow B, Wehr G, Fischer J, Hennies HC, **Hausser I**, Breitzkreutz D, Aufenvenne K, Stieler K, Tantcheva-Poór I, Weidinger S, Emmert S, Hamm H, Perusquia-Ortiz AM, Zaraeva I, Diem A, Giehl K, Fölster-Holst R, Kiekbusch K, Höger P, Ott H, Traupe H. S1 guidelines for the diagnosis and treatment of ichthyoses - update. *J Dtsch Dermatol Ges*. 2017 Oct;15(10):1053-1065. (IF: 2.865)

Petersen I, Dietel M, Geilenkeuser WJ, Mireskandari M, Weichert W, Steiger K, Scheel AH, Büttner R, **Schirmacher P, Warth A, Lasitschka F**, Schildhaus HU, Kirchner T, Reu S, Kreipe H, Länger F, Tiemann M, Schulte C, Jöhrens K. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®). *Pathol Res Pract*. 2017 Dec;213(12):1530-1535. (IF: 1.543)

Pfarr N, Darb-Esfahani S, **Leichsenring J, Taube E, Boxberg M, Braicu I, Jesinghaus M, Penzel R, Endris V, Noske A, Weichert W, Schirmacher P, Denkert C, Stenzinger A**. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with

transitional cell histology. *Genes Chromosomes Cancer*. 2017 Oct;56(10):758-766. (IF: 3.696)

Pfarr N, Penzel R, Endris V, Lier C, Flechtenmacher C, Volckmar AL, Kirchner M, Budczies J, Leichsenring J, Herpel E, Noske A, Weichert W, Schneeweiss A, Schirmacher P, Sinn HP, Stenzinger A. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. *Genes Chromosomes Cancer*. 2017 Apr;56(4):255-265. (IF: 3.696)

Pfarr N, Stenzinger A. Mutations of cancer-related genes in benign tumors: the example of hidradenoma papilliferum. *Hum Pathol*. 2017 Apr;62:246-247. (IF: 3.014)

Picard de Muller, G, Ait-Belkacem, R, Bonnel, D, **Longuespee, R**, & Stauber, J. Automated Morphological and Morphometric Analysis of Mass Spectrometry Imaging Data: Application to Biomarker Discovery. *J Am Soc Mass Spectrom*. 2017 Dec;28(12): 2635–2645. (IF: 2.786)

Pinna F, Bissinger M, Beuke K, Huber N, Longerich T, Kummer U, Schirmacher P, Sahle S, Breuhahn K. A20/TNFAIP3 Discriminates Tumor Necrosis Factor (TNF)-Induced NF- κ B from JNK Pathway Activation in Hepatocytes. *Front Physiol*. 2017 Aug 23;8:610. (IF: 4.134)

Polke M, Oelmann-Avendano J, **Warth A**, Heussel CP, Herth FJF, Eberhardt R. Successful treatment of a recurrent granulation polyp in the airways with high-dose-rate brachytherapy: a case report. *J Med Case Rep*. 2017 Oct 18;11(1):289. (IF: 0.69)

Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, **Lasitschka F**, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A. Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis. *J Hepatol*. 2018 Mar;68(3):421-430. (IF: 12.486)

Rabe T, Schweppe KW, Ebert AD, Mlynek-Kersjes ML, Elsässer M, Merkle E, Albring C, Bachmann A, Bitzer J, de Wilde RL, Egarter C, Föger T, Kiesel L, König K, Gattenlöhner S, Merki G, Nerlich A, Sängler N, **Sinn P**, Strowitzki T, Tinneberg H, Wallwiener M, Ziller M. Adenomyosis uteri. *Journal für Reproduktionsmedizin und Endokrinologie*. 2017 Jan; 14(5):211-218. (IF: 0.20)

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, **Roth W, Wiczorek K**, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. *Eur Urol*. 2017 Dec;72(6):888-896. (IF: 16.265)

Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, **Herpel E**, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C. Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. *Acta Neuropathol*. 2017 Aug;134(2):297-316. (IF: 12.213)

Rathinasamy A, Domschke C, Ge Y, Böhm HH, Dettling S, **Jansen D, Lasitschka F**, Umansky L, Gräler MH, Hartmann J, Herold-Mende C, Schuetz F, Beckhove P. Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. *Cancer Immunol Immunother.* 2017 May;66(5):593-603. (IF: 4.711)

Reiner T, Do TD, Klot MC, Hertzsch F, Seelmann K, **Gaida MM**, Weber MA, Gotterbarm T. MRI Findings in Patients After Small-Head Metal-on-Metal Total Hip Arthroplasty with a Minimum Follow-up of 10 Years. *J Bone Joint Surg Am.* 2017 Sep 20;99(18):1540-1546. (IF: 4.840)

Riedel F, Hennigs A, Marmé F, **Sinn P**, Lindel K, Gondos A, Smetanay K, Golatta M, Sohn C, Schuetz F, Heil J, Schneeweiss A. Veränderungen in der Anwendung und beim Outcome von Chemotherapie beim frühen Mammakarzinom in der letzten Dekade (2003–2014). *Senologie - Zeitschrift für Mammadiagnostik und –therapie.* 2017 Sep; 14(3):136-139. (IF: 0.03)

Rüschhoff J, Lebeau A, Kreipe H, **Sinn P**, Gerharz CD, Koch W, Morris S, Ammann J, Untch M. Nicht-interventionelle Untersuchung (NIU) HER2 Study Group. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. *Mod Pathol.* 2017 Feb;30(2):217-226. (IF: 5.728)

Safi S, Yamauchi Y, Rathinasamy A, Stamova S, Eichhorn M, **Warth A**, Rauch G, Dienemann H, Hoffmann H, Beckhove P. Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. *Oncoimmunology.* 2017 Sep 8;6(11):e1360458. (IF: 7.719)

Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, **Longerich T, Roessler S, Schirmacher P**, Manns MP, Illig T, Schlegelberger B, Skawran B. The microRNA-449 family inhibits TGF- β -mediated liver cancer cell migration by targeting SOX4. *J Hepatol.* 2017 May;66(5):1012-1021. (IF: 12.486)

Schecher S, Walter B, Falkenstein M, **Macher-Goeppinger S**, Stenzel P, Krümpelmann K, Hadaschik B, Perner S, Kristiansen G, Duensing S, **Roth W, Tagscherer KE**. Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. *Int J Cancer.* 2017 Oct 15;141(8):1643-1653. (IF: 6.513)

Schirmacher P. [Current state and perspectives in university pathology]. *Pathologe.* 2017 Jul;38(4):228. (IF: 0.509)

Schlitter AM, Segler A, Steiger K, Michalski CW, Jäger C, Konukiewitz B, Pfarr N, **Endris V**, Bettstetter M, Kong B, Regel I, Kleeff J, Klöppel G, Esposito I. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. *Sci Rep.* 2017 Feb 1;7:41064. (IF: 4.259)

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, **Herpel E**, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. *Lung Cancer.* 2017 Nov;113:121-127. (IF: 4.294)

Schneider MA, Christopoulos P, Muley T, **Warth A**, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F, Meister M. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. *Int J Oncol*. 2017 Feb;50(2):365-372. (IF: 3.079)

Schott S, Yang R, Stöcker S, Canzian F, Giese N, Bugert P, **Bergmann F**, Strobel O, Hackert T, Sohn C, Burwinkel B. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study. *Oncotarget*. 2017 Jun 27;8(40):67614-67625. (IF: 5.168)

Schroeder L, Boscolo-Rizzo P, Dal Cin E, Romeo S, Baboci L, Dyckhoff G, Hess J, **Lucena-Porcel C**, Byl A, Becker N, Alemany L, Castellsagué X, Quer M, León X, Wiesenfarth M, Pawlita M, Holzinger D. Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. *Eur J Cancer*. 2017 Mar;74:73-81. (IF: 6,029)

Schwamborn K, **Kriegsmann M**, Weichert W. MALDI imaging mass spectrometry - From bench to bedside. *Biochim Biophys Acta*. 2017 Jul;1865(7):776-783. (IF: 2.590)

Schwarze M, Weber MA, **Mechtersheimer G**, Lehner B, Renker EK. [Mazabraud and McCune-Albright syndromes in association : A case of two very rare orthopaedic tumour entities]. *Orthopade*. 2017 Sep;46(9):776-780. (IF: 0.629)

Seelbach-Göbel B, Beckmann MW, Blohmer JU, **Sinn HP**. Erlangen, 31.01.2017 – 243rd Statement by the German Society of Gynecology and Obstetrics (DGGG) in Response to the Call for Data on the Safety of PIP Silicone Breast Implants and the Possible Association between Breast Implants and ALCL by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) of the European Commission. *Geburtshilfe und Frauenheilkunde*. 2017 Jun; 77(06):617-619. (IF: 1.175)

Sinn HP, Schneeweiss A, **Keller M**, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. *BMC Cancer*. 2017 Feb 13;17(1):124. (IF: 3.288)

Sproll C, Freund AK, Hassel A, Hölbling M, Aust V, Storb SH, Handschel J, Teichmann C, Depprich R, Behrens B, Neves RP, Kübler NR, Kaiser P, Baldus SE, **Tóth C**, Kaisers W, Stoecklein NH. Immunohistochemical detection of lymph node-DTCs in patients with node-negative HNSCC. *Int J Cancer*. 2017 May 1;140(9):2112-2124. (IF: 6.513)

Stefanovic S, Wirtz R, Deutsch TM, Hartkopf A, **Sinn P**, Varga Z, Sobottka B, Sotiris L, Taran FA, Domschke C, Hennigs A, Brucker SY, Sohn C, Schuetz F, Schneeweiss A, Wallwiener M. Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. *Oncotarget*. 2017 May 19;8(31):51416-51428. (IF: 5.168)

Steinemann DC, Zerz A, Müller PC, Sauer P, Schaible A, **Lasitschka F**, Schwarz AC, Müller-Stich BP, Linke GR. Laparoscopic transgastric circumferential stapler-assisted vs. endoscopic esophageal mucosectomy in a porcine model. *Endoscopy*. 2017 Jul;49(7):668-674. (IF: 6.107)

Stenzinger A, Weichert W. Genetic Profiling of Cancers of the Digestive System: Biological Insights and Clinical Implications. *Pathobiology*. 2017;84(6):306-322. (IF: 1.703)

Stichel D, Middleton AM, **Müller BF**, Depner S, Klingmüller U, **Breuhahn K***, Matthäus F*. An individual-based model for collective cancer cell migration explains speed dynamics and phenotype variability in response to growth factors. *NPJ Syst Biol Appl*. 2017 Mar 3;3:5. (IF: new journal, IF unknown)

Strobel O, Hank T, Hinz U, **Bergmann F**, Schneider L, Springfield C, Jäger D, **Schirmacher P**, Hackert T, Büchler MW. Pancreatic Cancer Surgery: The New R-status Counts. *Ann Surg*. 2017 Mar;265(3):565-573. (IF: 8.980)

Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, Wu Y, Anzeneder T, Wang W, Windisch P, Kirchgäßner M, Melling N, Kneisel N, Büttner R, Deuschle U, **Sinn HP**, Schneeweiss A, Heck S, Kaulfuss S, Hess-Stumpp H, Okun JG, Sauter G, Lykkesfeldt AE, Zapatka M, Radlwimmer B, Lichter P, Tönjes M. The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER-negative breast cancer. *Oncogene* 2017 Mar; 36(29):4124-4134. (IF: 7.509)

Thunnissen E, Borczuk AC, Flieder DB, Witte B, Beasley MB, Chung JH, Dacic S, Lantuejoul S, Russell PA, den Bakker M, Botling J, Brambilla E, de Cuba E, Geisinger KR, Hiroshima K, Marchevsky AM, Minami Y, Moreira A, Nicholson AG, Yoshida A, Tsao MS, **Warth A**, Duhig E, Chen G, Matsuno Y, Travis WD, Butnor K, Cooper W, Mino-Kenudson M, Motoi N, Poleri C, Pelosi G, Kerr K, Aisner SC, Ishikawa Y, Buettner RH, Keino N, Yatabe Y, Noguchi M. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. *J Thorac Oncol*. 2017 Feb;12(2):334-346. (IF: 6.595)

Toberer F, Happle R, Schneiderbauer R, **Hausser I**, Kröhl V, Epple A, Moog U, Enk AH, Lonsdorf AS. At first sight or second glance: clinical presentation of mosaic manifestations of autosomal dominant skin disorders - a case series. *J Eur Acad Dermatol Venereol*. 2017 Nov;31(11):1912-1915. (IF: 3.528)

Tóth C, Funke S, Nitsche V, Liverts A, Zlachevska V, Gasis M, Wiek C, Hanenberg H, Mahotka C, **Schirmacher P**, Heikaus S. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling. *Cell Commun Signal*. 2017 May 2;15(1):16. (IF: 3.943)

Tóth C, Sükösd F, Valicsek E, **Herpel E**, **Schirmacher P**, **Renner M**, **Mader C**, Tizslavicz L, Kriegsmann J. Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer. *Int J Mol Med*. 2017 Nov;40(5):1457-1465. (IF: 2.341)

Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, **Sinn P**, Thill M, Thomssen C, Harbeck N, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). *Geburtshilfe Frauenheilkd*. 2017 Jun;77(6):633-644.

(IF: 1.175)

Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SW, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, **Sinn P**, Thill M, Thomssen C, Harbeck N, Liedtke C. Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens: Meinungsbild deutscher Experten zur 15. Internationalen St. Gallen-Konsensuskonferenz (Wien 2017). *Senologie - Zeitschrift für Mammadiagnostik und -therapie*. 2017 Sept; 14(03):147-159. (IF: 0.03)

Van Damme T, Gardeitchik T, Mohamed M, Guerrero-Castillo S, Freisinger P, Guillemyn B, Kariminejad A, Dalloyaux D, van Kraaij S, Lefeber DJ, Syx D, Steyaert W, De Rycke R, Hoischen A, Kamsteeg EJ, Wong SY, van Scherpenzeel M, Jamali P, Brandt U, Nijtmans L, Korenke GC, Chung BHY, Mak CCY, **Hausser I**, Kornak U, Fischer-Zirnsak B, Strom TM, Meitinger T, Alanay Y, Utine GE, Leung PKC, Ghaderi-Sohi S, Coucke P, Symoens S, De Paepe A, Thiel C, Haack TB, Malfait F, Morava E, Callewaert B, Wevers RA. Mutations in ATP6V1E1 or ATP6V1A Cause Autosomal-Recessive Cutis Laxa. *Am J Hum Genet*. 2017 Feb 2;100(2):216-227. (IF: 9.025)

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, **Sinn P**, Sahin U, Bartlett J, Viale G. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. *Breast Cancer Res*. 2017 May 11;19(1):55. (IF: 6.345)

Viarisio D, Müller-Decker K, Hassel JC, Alvarez JC, **Flechtenmacher C**, Pawlita M, Gissmann L, Tommasino M. The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. *J Invest Dermatol*. 2017 Jan;137(1):261-264. (IF: 6.287)

Volckmar AL, Leichsenring J, Flechtenmacher C, Pfarr N, Siebolts U, Kirchner M, Budczies J, Bockmayr M, Ridinger K, Lorenz K, Herpel E, Noske A, Weichert W, Klauschen F, Schirmacher P, Penzel R, Endris V, Stenzinger A. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway. *Genes Chromosomes Cancer*. 2017 Jan;56(1):11-17. (IF: 3.696)

von Laffert M, **Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, Griesinger F, Dietel M, Grohé C.** ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). *Lung Cancer*. 2017 Jan;103:1-5. (IF: 4.294)

Wannhoff A, Rupp C, Friedrich K, Knierim J, **Flechtenmacher C, Weiss KH, Stremmel W, Gotthardt DN.** Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. *Dig Dis Sci*. 2017 Feb;62(2):510-516. (IF: 2.22)

Warth A. Spread through air spaces (STAS): a comprehensive update. *Transl Lung Cancer Res.* 2017 Oct;6(5):501-507. (IF:1.757)

Warth A, Beasley MB, Mino-Kenudson M. Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS). *J Thorac Oncol.* 2017 Feb;12(2):176-178. (IF: 6.595)

Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C, **Knaub M, Thomann S, Bissinger M, Wan S, Rössler S,** Becker D, Gretz N, Lang H, **Bergmann F,** Ustiyan V, Kalin TV, **Singer S,** Lee JS, Marquardt JU, **Schirmacher P,** Kalinichenko VV, **Breuhahn K.** Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. *Gastroenterology.* 2017 Jun;152(8):2037-2051.e22. (IF: 18.392)

Wieland E, Rodriguez-Vita J, Liebler SS, **Mogler C,** Moll I, Herberich SE, Espinet E, **Herpel E,** Menuchin A, Chang-Claude J, Hoffmeister M, Gebhardt C, Brenner H, Trumpp A, Siebel CW, Hecker M, Utikal J, Sprinzak D, Fischer A. Endothelial Notch1 Activity Facilitates Metastasis. *Cancer Cell.* 2017 Mar 13;31(3):355-367. (IF: 27.407)

Winkler JK, Schneiderbauer R, Bender C, Sedlacek O, Fröhling S, **Penzel R,** Enk A, Hassel JC. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. *Br J Dermatol.* 2017 Feb;176(2):498-502. (IF: 4.706)

Wörns MA, Galle PR, Zeuzem S, **Schirmacher P,** Manns M, Vogel A. Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. *Dtsch Arztebl Int.* 2017 Sep 4;114(35-36):597-602. (IF: 4.257)

Wohlfarth C, Schmitteckert S, Härtle JD, Houghton LA, Dweep H, Fortea M, Assadi G, Braun A, Mederer T, Pöhner S, Becker PP, Fischer C, Granzow M, Mönnikes H, Mayer EA, Sayuk G, Boeckxstaens G, Wouters MM, Simrén M, Lindberg G, Ohlsson B, Schmidt PT, Dlugosz A, Agreus L, Andreasson A, D'Amato M, Burwinkel B, Bermejo JL, Röth R, **Lasitschka F,** Vicario M, Metzger M, Santos J, Rappold GA, Martinez C, Niesler B. miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. *Sci Rep.* 2017 Oct 31;7(1):14680. (IF: 4.259)

Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, **Hausser I,** Bugert P, Michel MS, Boutros M. Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. *Mol Cell Proteomics.* 2017 Jun;16(6):998-1008. (IF: 6.540)

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehnert N, **Penzel R, Weichert W,** Ho AD, **Schirmacher P,** Goldschmidt H, **Andrulis M,** Raab MS. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. *Oncogenesis.* 2017 May 15;6(5):e337. (IF: 4.143)

Yamauchi Y, Safi S, Muley T, **Warth A,** Herth FJF, Dienemann H, Hoffmann H, Eichhorn ME. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. *Lung Cancer.* 2017 Dec;114:62-67. (IF: 4.294)

Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, **Mechtersheimer G**, Daugaard S, Sciort R, Collin F, Messiou C, Grünwald V, Gronchi A, van der Graaf W, Wardelmann E, Judson I. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. *Acta Oncol.* 2017 Jul;56(7):1013-1020. (IF: 3.156)

Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Öllinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Höchst B, Wohlleber D, Jörs S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Hüser N, Davis RJ, **Tschaharganeh DF**, Rad R, Weber A, Zender L, Haller D, Heikenwalder M. Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. *Cancer Cell.* 2017 Jun 12;31(6):771-789.e6. (IF: 27.407)

Zhao J, Dinkel J, **Warth A**, **Penzel R**, Reinmuth N, **Schnabel P**, Muley T, Meister M, Zabeck H, Steins M, Yang JY, Zhou Q, Schlemmer HP, Herth FJF, Kauczor HU, Heussel CP. CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation. *PLoS One.* 2017 Sep 26;12(9):e0182741. (IF: 2.806)

Zhou X, Xie L, **Bergmann F**, **Endris V**, Strobel O, Büchler MW, Kroemer G, Hackert T, Fortunato F. The bile acid receptor FXR attenuates acinar cell autophagy in chronic pancreatitis. *Cell Death Discov.* 2017 Jun 19;3:17027. (IF: new journal, IF unknown)

Zhou X, Xie L, Xia L, **Bergmann F**, Büchler MW, Kroemer G, Hackert T, Fortunato F. RIP3 attenuates the pancreatic damage induced by deletion of ATG7. *Cell Death Dis.* 2017 Jul 13;8(7):e2918. (IF: 5.965)

Zimmer AD, Kim GJ, Hotz A, Bourrat E, **Hausser I**, Has C, Oji V, Stieler K, Vahlquist A, Kunde V, Weber B, Radner FPW, Leclerc-Mercier S, Schlipf N, Demmer P, Küsel J, Fischer J. Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function. *Br J Dermatol.* 2017 Aug;177(2):445-455. (IF: 4.706)

Zschäbitz S, **Lasitschka F**, Hadaschik B, Hofheinz RD, Jentsch-Ullrich K, Grüner M, Jäger D, Grüllich C. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. *Eur J Cancer.* 2017 May;76:1-7. (IF: 6.029)

Book chapters

Casadonte R, Longuespée R, Kriegsmann J, **Kriegsmann M.** (2017). MALDI IMS and Cancer Tissue Microarrays. In: Advances in Cancer Research: Applications of Mass Spectrometry Imaging to Cancer. Richard R. Drake and Liam A. McDonnell (eds.), Adv Cancer Res. 2017;134:173-200. ISBN: 978-0-12-805249-5.

Hausser, I. (2017). Morphologische Grundlagen erblicher Bindegewebserkrankungen. In: Das Ehlers-Danlos-Syndrom. Eine interdisziplinäre Herausforderung. A. Luttkus (Hrsg), 2. Aufl., Walter de Gruyter GmbH, Berlin/Boston, S. 31-38. ISBN: 978-3-11-047364-3.

Lasitschka F. (2017). Grawitz, Paul Albert (1850–1932). In: Pioneers in Pathology, Encyclopedia of Pathology. J.G. van den Tweel (ed.). S. 194-196. ISBN: 978-3-319-41994-7.

Lasitschka F. (2017). Henle, Jacob (1809–1885). In: Pioneers in Pathology, Encyclopedia of Pathology. J.G. van den Tweel (ed.). S. 210-212. ISBN 978-3-319-41994-7.

Patents

Gydnia, G.
Internationale Patentanmeldung Nr. PCT/EP2017/055216
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: HMGB1 Mutants

Gydnia, G.
Australische Patentanmeldung Nr. 130083
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.
Kanadische Patentanmeldung Nr. 130083
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.
Belgische Patentanmeldung Nr. 130083EP2
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.
Schweizer Patentanmeldung Nr. 130083EP2
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.
Deutsche Patentanmeldung Nr. 130083EP2
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.
Dänische Patentanmeldung Nr. 130083EP2
Anmelder: Ruprecht-Karls-Universität Heidelberg
Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Spanische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Finnische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Französische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Britische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Irische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Italienische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Niederländische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice Kulturen

Gydnia, G.

Norwegische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice

Kulturen

Gydnia, G.

Polnische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice
Kulturen

Gydnia, G.

Schwedische Patentanmeldung Nr. 130083EP2

Anmelder: Ruprecht-Karls-Universität Heidelberg

Stichwort: Umfassende Energiestoffwechselprofilierung maligner Tumore in ex vivo tissue slice
Kulturen